Back to UBS Group AG

AVTX
Showing 8 of 19 quarters

Position history for UBS Group AG's holdings in AVALO THERAPEUTICS INC

UBS Group AG holds 1.1M shares of AVTX (AVALO THERAPEUTICS INC), worth $17M as of 2026-Q1. The position was increased (+139.0% shares). AVTX represents 0.0% of UBS Group AG's portfolio.

Current Value

$17M

Current Shares

1.1M

Total Value Change

+$17M

Total Shares Change

+1.1M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q1
Latest
Increased
1.1M
+139.0%
$17M0.0%$18.85
46
2025-Q4
Increased
477,816
+956.9%
$8.7M0.0%$17.81
44
2025-Q3
Decreased
45,208
-46.0%
$574,5940.0%$13.02
0
2025-Q2
Decreased
83,724
-15.4%
$417,7830.0%$4.78
0
2025-Q1
Increased
98,951
+0.4%
$792,5980.0%$8.46
25
2024-Q4
Increased
98,519
+1506.1%
$731,9960.0%$7.80
40
2024-Q3
Increased
6,134
+71.2%
$58,2730.0%$9.40
21
2024-Q2
Decreased
3,583
-53.5%
$44,6800.0%$12.47
0

Other major holders of AVTX: FMR LLC, Avoro Capital Advisors LLC, VANGUARD GROUP INC, Point72 Asset Management, L.P., FARALLON CAPITAL MANAGEMENT, L.L.C.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used